New drug classes, discovered at machine speed

AI proven in antibacterials, expanding into new therapeutic areas

Built to explore new chemical space and discover oral small molecules

ArrePath begins with the desired candidate profile, then deploys target-specific AI/ML workflows to evaluate novel chemistry while optimizing potency and developability in parallel.

Discovery at machine scale

~4 weeks

Rapid program start

Target selection to validated, deployed target-specific AI/ML workflows

1M+

Machine-scale exploration

Molecules evaluated per design cycle

Novel chemistry

6 new antibacterial classes

6 new MOAs discovered in 4 years

Quarterly bar chart of best-in-series percent oral bioavailability for the lead program from 3Q23 through 1Q26 — bars stay at or below 22% through 2Q25, then jump to roughly 64% in 3Q25, 84% in 4Q25, and 89% in 1Q26 after the oral bioavailability model was deployed.

Solving oral bioavailability — one of medicinal chemistry’s hardest problems

A model trained on public data alone generalized to a novel chemical series it had never seen.
Applied across every molecule made before deployment, it identified the progenitor of the lead series and helped advance oral bioavailability from below 10% to above 80%.
The result demonstrates simultaneous optimization of potency and developability rather than a potency-first retrofit.

Proven in antibacterials. Built to expand beyond.

ArrePath validated the platform by discovering six new antibacterial classes with six new mechanisms of action in four years.

The same platform is now being applied to validated targets where oral-small-molecule options are limited.

ArrePath pipeline: Project 1 outpatient UTI oral LpxH inhibitor in late lead optimization; Project 2 mycobacterial lung disease programs targeting M. abscessus, broad-spectrum NTM, and tuberculosis; Project 3 first oral small molecule against a validated immunology target; Project 4 first oral small molecule against a validated inflammation target.

Strategy & Pipeline →

Get in touch

We welcome partnering and investor conversations about the platform and our programs.